Literature DB >> 16525632

Survivin associates with cell proliferation in renal cancer cells: regulation of survivin expression by insulin-like growth factor-1, interferon-gamma and a novel NF-kappaB inhibitor.

Akinori Sato1, Mototsugu Oya, Keiichi Ito, Ryuichi Mizuno, Yutaka Horiguchi, Kazuo Umezawa, Masamichi Hayakawa, Masaru Murai.   

Abstract

Although survivin has been widely recognized as an attractive target for cancer therapy, the exact mechanism regarding the regulation of survivin and its effect on cell proliferation have yet to be clearly defined in renal cell carcinoma (RCC). We investigated herein the association between survivin expression and cell proliferation in a RCC cell line, KU19-20. In KU19-20 cells, cell proliferation and survivin expression were significantly induced by IGF-1, whereas they were inhibited by a novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin (DHMEQ) and IFN-gamma. The combination of DHMEQ and IFN-gamma inhibited cell proliferation synergistically with a pronounced attenuation of survivin expression. Furthermore, treatment with survivin-specific siRNA reduced expression of survivin and significantly inhibited cell proliferation. Survivin expression was thus associated with cell proliferation in KU19-20 cells. The regulation of survivin by IFN-gamma and/or an NF-kappaB inhibitor may therefore be a potential treatment modality for RCC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16525632

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  8 in total

1.  MicroRNA-1826 directly targets beta-catenin (CTNNB1) and MEK1 (MAP2K1) in VHL-inactivated renal cancer.

Authors:  Hiroshi Hirata; Yuji Hinoda; Koji Ueno; Koichi Nakajima; Nobuhisa Ishii; Rajvir Dahiya
Journal:  Carcinogenesis       Date:  2011-12-17       Impact factor: 4.944

2.  Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis.

Authors:  Rui-Hong Wang; Yin Zheng; Hyun-Seok Kim; Xiaoling Xu; Liu Cao; Tyler Luhasen; Mi-Hye Lee; Cuiying Xiao; Athanassios Vassilopoulos; Weiping Chen; Kevin Gardner; Yan-Gao Man; Mien-Chie Hung; Toren Finkel; Chu-Xia Deng
Journal:  Mol Cell       Date:  2008-10-10       Impact factor: 17.970

3.  Increased survivin expression confers chemoresistance to tumor-associated endothelial cells.

Authors:  Jenilyn J Virrey; Shengxi Guan; Wei Li; Axel H Schönthal; Thomas C Chen; Florence M Hofman
Journal:  Am J Pathol       Date:  2008-07-03       Impact factor: 4.307

4.  Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model.

Authors:  J S P Yuen; M Y Sim; H G Siml; T W Chong; W K O Lau; C W S Cheng; H Huynh
Journal:  Br J Cancer       Date:  2011-03-15       Impact factor: 7.640

5.  Down-regulation of NF kappa B activation is an effective therapeutic modality in acquired platinum-resistant bladder cancer.

Authors:  Yujiro Ito; Eiji Kikuchi; Nobuyuki Tanaka; Takeo Kosaka; Eriko Suzuki; Ryuichi Mizuno; Toshiaki Shinojima; Akira Miyajima; Kazuo Umezawa; Mototsugu Oya
Journal:  BMC Cancer       Date:  2015-04-29       Impact factor: 4.430

6.  Survivin in Insulin-Like Growth Factor-Induced Resistance to Lapatinib in Head and Neck Squamous Carcinoma Cells.

Authors:  Christine E Lehman; Rolando E Mendez; Michael I Dougherty; Amir Allak; Oluwayemisi L Adejumo; Linnea E Taniguchi; Ashraf Khalil; Daniel G Gioeli; Mark J Jameson
Journal:  Front Oncol       Date:  2019-01-23       Impact factor: 6.244

7.  Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types.

Authors:  Xiang Ling; Diane Calinski; Asher A Chanan-Khan; Muxiang Zhou; Fengzhi Li
Journal:  J Exp Clin Cancer Res       Date:  2010-01-22

8.  Immunohistochemical expression of insulin-like growth factor-1Ec in primary endometrial carcinoma: Association with PTEN, p53 and survivin expression.

Authors:  Aggelis Stavropoulos; Michail Varras; Anastassios Philippou; Thivi Vasilakaki; Viktoria-Konstantina Varra; Fani-Niki Varra; Aikaterini Tsavari; Andreas C Lazaris; Michael Koutsilieris
Journal:  Oncol Lett       Date:  2020-10-29       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.